Eli Lilly shares are trading higher after the company raised its FY23 guidance. The company also reported better-than-expected Q2 earnings, including strong Mounjaro sales growth.
Portfolio Pulse from Benzinga Newsdesk
Eli Lilly has raised its FY23 guidance and reported better-than-expected Q2 earnings, including strong sales growth for Mounjaro.
August 08, 2023 | 1:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eli Lilly's stock is trading higher following the company's raised FY23 guidance and better-than-expected Q2 earnings, including strong Mounjaro sales.
Eli Lilly's raised FY23 guidance and strong Q2 earnings, particularly the robust sales growth of Mounjaro, are positive indicators of the company's financial health. This has led to an increase in the company's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100